Enhancing the adoption of NOACs for treatment of atrial fibrillation – driving payer awareness of AF screening.

With loss of exclusivity on the horizon, our client sought to maximise the uptake of NOAC’s for the treatment of Atrial Fibrillation across key markets by gaining reimbursement for the implementation of novel screening programs.

Eradigm conducted an extensive landscape assessment of previously implemented screening programs across disease indications, identifying market-specific and cross-market learnings and enabling our client to accelerate the implementation and reimbursement of Atrial Fibrillation screening programmes across its key markets.